Carboplatin and paclitaxel treatment is effective in advanced anal cancer

Oncology (Switzerland)

Volumn 87, Issue 2, 2014, Pages 125-132

  Kim, Richard ^a   Byer, Jennifer ^b   Fulp, William J ^a   Mahipal, Amit ^a   Dinwoodie, William ^a   Shibata, David ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Anal cancer; Carboplatin; Paclitaxel

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANUS CANCER; ANUS SQUAMOUS CELL CARCINOMA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DRUG EFFICACY; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; ANEMIA; ANUS CARCINOMA; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FOLLOW UP; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANUS NEOPLASMS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84903864979     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000361051     Document Type: Article

References (21)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Palefsky JM: Anal human papillomavirus infection and anal cancer in HIV-positive individuals: an emerging problem. AIDS 1994; 8: 283-295.
3. Flam M, et al: Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996; 14: 2527-2539.
4. Faivre C, et al: 5-Fluorouracil and cisplatin combination chemotherapy for metastatic squamous-cell anal cancer. Bull Cancer 1999; 86: 861-865.
5. Tanum G: Treatment of relapsing anal carcinoma. Acta Oncol 1993; 32: 33-35.
6. Kelly K, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19: 3210-3218.
7. Moosmann P, et al: Weekly paclitaxel and carboplatin combination chemotherapy in patients with advanced squamous cell carcinoma of the head and neck. Onkologie 2003; 26: 568-572.
8. McGuire WP, et al: Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 1996; 14: 792-795.
9. Pawlik TM, et al: Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multicenter analysis. Ann Surg Oncol 2007; 14: 2807-2816.
10. Abbas A, Nehme E, Fakih M: Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy. Anticancer Res 2011; 31: 4637-4640.
11. Hainsworth JD, et al: Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a phase II trial. Cancer 2001; 92: 642-649.
12. Wilking N, et al: Phase II study of combination bleomycin, vincristine and high-dose methotrexate (BOM) with leucovorin rescue in advanced squamous cell carcinoma of the anal canal. Cancer Chemother Pharmacol 1985; 15: 300-302.
13. Jhawer M, et al: Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and bleomycin-CCNU in patients with advanced cancer of the anal canal: an Eastern Cooperative Oncology Group study E7282. Invest New Drugs 2006; 24: 447-454.
14. Le LH, Chetty R, Moore MJ: Epidermal growth factor receptor expression in anal canal carcinoma. Am J Clin Pathol 2005; 124: 20-23.
15. Lukan N, et al: Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology 2009; 77: 293-299.
16. De Dosso S, et al: Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma. Tumori 2010; 96: 627-628.
17. Hitt R, et al: Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol 2012; 23: 1016-1022.
18. Wahl AF, et al: Loss of normal p53 function confers sensitization to TAXOL by increasing G2/M arrest and apoptosis. Nat Med 1996; 2: 72-79.
19. Scheffner M, et al: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-1136.
20. Daling JR, et al: Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004; 101: 270-280.
21. Kim S, et al: DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma. Ann Oncol 2013; 24: 3045-3050.